Finance

Lists
Why is FATE down 5.76%?
Dive Deeper
FATE:NASDAQ
Fate Therapeutics Inc
$2.29
-5.76%
(-0.14) 1D
$2.30
+0.44% (+0.0100)
After hours
Closed: Oct 6, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FATE...
Open
$2.43
High
$2.49
Low
$2.28
Mkt. cap
261.97M
Avg. vol.
1.47M
Volume
1.14M
52-wk high
$3.23
52-wk low
$0.95
EPS
-$1.05
Beta
2.52
Shares outstanding
119.82M
No. of employees
161
Open
$2.43
High
$2.49
Low
$2.28
Mkt. cap
261.97M
Avg. vol.
1.47M
Volume
1.14M
52-wk high
$3.23
52-wk low
$0.95
EPS
-$1.05
Beta
2.52
Shares outstanding
119.82M
No. of employees
161
News stories
From web sources and news partners
About Fate Therapeutics Inc
CEOScott Wolchko
Employees161
Founded2007
Headquarters-
SectorBiotechnology
Websitefatetherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to FATE in the past 3 months
Buy
Buy
4
Hold
3
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for FATE in the last 3 months.
Highest
Current $2.29
$8.00 (+249.34%)
Average
$6.70 (+192.58%)
Lowest
$3.50 (+52.84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gil Blum
Needham
Hold
Maintained
-
-
10/05/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$8.00
+249.3%
08/17/2026
Unknown Analyst
Wedbush
Buy
Maintained
$7.00
+205.7%
08/14/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$8.00
+249.3%
08/14/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
$3.50
+52.8%
08/14/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$7.00
+205.7%
07/09/2026
Tazeen Ahmad
Bank of America Securities
Hold
Reiterated
$2.20
-3.9%
05/21/2026
Roger Song
Jefferies
Buy
Initiated
$4.00
+74.7%
05/19/2026
Martin Fan
Wedbush
Buy
Maintained
$7.00
+205.7%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.74M
1.37M
1.30M
2.08M
Cost of goods sold
25.84M
9.50M
24.70M
24.39M
Cost of revenue
25.84M
9.50M
24.70M
24.39M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.64M
25.50M
9.60M
8.83M
Operating expense
10.64M
25.50M
9.60M
8.83M
Total operating expenses
36.48M
34.99M
34.30M
33.22M
Operating income
-34.74M
-33.62M
-33.00M
-31.13M
Other non operating income
-90.00K
127.00K
-80.00K
-580.00K
EBT including unusual items
-32.25M
-32.37M
-31.21M
-30.16M
EBT excluding unusual items
-32.25M
-31.27M
-31.21M
-30.16M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32.25M
-32.37M
-31.21M
-30.16M
Net profit margin
-1,852.38%
-2,364.79%
-2,402.85%
-1,448.56%
Earnings per share
-0.27
-0.27
-0.26
-0.25
Interest and investment income
2.58M
2.22M
1.87M
1.56M
Interest expense
-
-
-
-
Net interest expenses
2.58M
2.22M
1.87M
1.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
-31.51M
-30.56M
-30.08M
-28.35M
Gain or loss from assets sale
-
45.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps